Elanco Animal Health (ELAN) Investor presentation summary

Strategic positioning and industry overview

• Operates in over 90 countries with $4.7B projected 2025 revenue, split nearly evenly between pet health and farm animal segments.

• Holds #1 position in pet health retail and #2 in global farm animal health, with 10 blockbuster products exceeding $100M annual revenue.

• Animal health industry expected to grow from $42B to $60B, driven by innovation, brand loyalty, and economic value orientation.

• Global pet ownership and spending are rising, especially in emerging markets, with omnichannel and subscription models fueling growth.

• Protein consumption is increasing, supported by dietary trends, aging populations, and new health guidelines.

Growth, innovation, and financial performance

• Organic constant currency revenue growth improved from -3% in 2022 to 7% in 2025.

• Innovation pipeline (“Big 6”) expected to deliver $1.15B incremental revenue in 2026, with next wave targeting 5–6 blockbuster approvals by 2031.

• 2025 revenue reached $4.7B, with the U.S. accounting for 47% and international markets 53%.

• Top products include Advantage, AdTab, Seresto, Credelio, Rumensin, Maxiban, and Monteban, with strong growth in Credelio Quattro (59% CC growth).

• Adjusted net income for 2025 was $473M, with adjusted EBITDA at $901M and a margin of 19.2%.

Strategic frameworks and operational focus

• Pet health strategy emphasizes omnichannel offerings, innovation in parasiticides, dermatology, pain, and vaccines, and maximizing product access and awareness.

• Farm animal strategy focuses on efficiency, disease prevention, sustainability, and comprehensive product offerings, including medicated feed additives and vaccines.

• IPP strategy centers on delivering innovation, strengthening portfolio diversity, and improving productivity and cash flow.

• Executive team is experienced in driving growth, innovation, and operational excellence across global markets.